
Corcept Therapeutics Incorporated CORT
$ 40.98
2.78%
Quarterly report 2025-Q3
added 11-04-2025
Corcept Therapeutics Incorporated Total Non Current Liabilities 2011-2026 | CORT
Annual Total Non Current Liabilities Corcept Therapeutics Incorporated
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 2.29 M | 239 K | - | - | 12.6 M | 24.5 M | 29.3 M | 29 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 29.3 M | 239 K | 16.3 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
409 K | - | 1052.0 % | $ 415 M | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
263 M | $ 18.38 | -0.68 % | $ 2.7 B | ||
|
Amgen
AMGN
|
37.2 B | $ 344.65 | 0.81 % | $ 185 B | ||
|
Arrowhead Pharmaceuticals
ARWR
|
686 M | $ 71.99 | 3.84 % | $ 9.63 B | ||
|
Biogen
BIIB
|
9.03 B | $ 178.18 | -0.95 % | $ 25.9 B | ||
|
I-Mab
IMAB
|
131 M | - | - | $ 866 M | ||
|
Aytu BioScience
AYTU
|
42.1 M | $ 2.65 | 1.92 % | $ 16.6 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | ||
|
Adagene
ADAG
|
158 M | $ 2.96 | 7.64 % | $ 167 M | ||
|
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M | ||
|
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
1.63 M | $ 4.16 | 3.74 % | $ 9.05 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | ||
|
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | ||
|
Alterity Therapeutics Limited
ATHE
|
73.6 K | $ 3.18 | 0.32 % | $ 7.65 B | ||
|
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | ||
|
Compugen Ltd.
CGEN
|
39.9 M | $ 1.86 | 1.1 % | $ 167 M | ||
|
Aptose Biosciences
APTO
|
10.2 M | - | -45.71 % | $ 1.2 M | ||
|
Acasti Pharma
ACST
|
12.2 M | - | 4.01 % | $ 150 M | ||
|
Celldex Therapeutics
CLDX
|
17.3 M | $ 24.86 | 1.06 % | $ 1.6 M | ||
|
Cellectis S.A.
CLLS
|
109 M | $ 3.87 | 2.22 % | $ 116 M | ||
|
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
168 M | $ 1.41 | - | $ 264 M | ||
|
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | ||
|
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - | ||
|
Allena Pharmaceuticals
ALNA
|
10.2 M | - | 3.16 % | $ 1.9 M | ||
|
Ascendis Pharma A/S
ASND
|
101 M | $ 224.87 | -0.54 % | $ 5 B | ||
|
Ampio Pharmaceuticals
AMPE
|
3.53 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
106 M | - | - | $ 10.1 M | ||
|
Aravive
ARAV
|
10.2 M | - | -13.39 % | $ 1.45 M | ||
|
BioNTech SE
BNTX
|
341 M | $ 110.01 | -3.29 % | $ 27.2 B | ||
|
Athira Pharma
ATHA
|
876 K | - | - | $ 269 M | ||
|
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M | ||
|
Autolus Therapeutics plc
AUTL
|
50.6 M | $ 1.39 | 1.5 % | $ 355 M | ||
|
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | ||
|
AVROBIO
AVRO
|
276 K | - | 1083.1 % | $ 745 M | ||
|
Cardiff Oncology
CRDF
|
451 K | $ 1.73 | -1.43 % | $ 82.4 M | ||
|
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
23.6 M | - | -15.15 % | $ 60.3 M | ||
|
DBV Technologies S.A.
DBVT
|
7.14 M | $ 21.75 | 0.65 % | $ 2.11 B | ||
|
Brickell Biotech
BBI
|
146 K | - | -5.38 % | $ 6.06 M | ||
|
Amneal Pharmaceuticals
AMRX
|
2.42 B | $ 14.25 | 4.13 % | $ 4.4 B | ||
|
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | ||
|
Atreca
BCEL
|
12.6 M | - | -11.76 % | $ 5.79 M | ||
|
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | ||
|
Acer Therapeutics
ACER
|
244 K | - | 2.71 % | $ 14 M | ||
|
BioCryst Pharmaceuticals
BCRX
|
44.7 M | $ 6.72 | 2.05 % | $ 1.39 B |